Sunnyvale, CANCT07232355Now EnrollingIRB Ready

Human Papilloma Virus Clinical Trial in Sunnyvale, CA

Access cutting-edge human papilloma virus treatment through this clinical trial at a research site in Sunnyvale. Study-provided care at no cost to qualified participants.

Sponsored by Atila Biosystems Inc.

Quick Self-Assessment

See if you qualify for this Sunnyvale location

Preparing your pre-screening questions…

Expert Care in Sunnyvale

Access human papilloma virus specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related human papilloma virus treatment provided free

Apply for This Sunnyvale Location

Check if you qualify for this human papilloma virus clinical trial in Sunnyvale, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Sunnyvale

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Sunnyvale site if eligible
  4. 4Begin participation

About This Human Papilloma Virus Study in Sunnyvale

In May 2018, the World Health Organization (WHO) launched a strategy to eliminate cervical cancer. While this strategy seeks to achieve coverage of 70% in disease testing and 90% in treatment by 2030, it is estimated that these goals will not be achieved by most low- and middle- income (LMICs) countries until 2120 under existing conditions. Presently, more than 90% of worldwide cervical cancer cases occur in LMICs. To accelerate this timeline, there is an urgent need for accurate, affordable and rapid testing that can facilitate same-day screening-and-treatment of cervical precancer. The AmpFire® human papillomavirus (HPV) test (Atila Biosystems, CA) has the potential to meet these needs. The test has been adapted to classify HPV positive women into four categories according to their risk for cervical cancer development based on the specific HPV type found during the test. Moreover, results can be delivered in less than 20 minutes for the highest risk HPV type, and less than an hour for the remaining HPV types. This is a potential game changer for countries where treating all HPV positive women is unfeasible. A combination of HPV test with other image-based triage strategies can further reduce overtreatment while reaching the most at-risk women. The goal of this project is to evaluate the performance and feasibility of an innovative same-day screening-and-treatment strategy in Honduras based on the AmpFire® HPV test combined with imaging triage using artificial intelligence via the Automated Visual Evaluation (AVE). Additionally, the investigators will evaluate the cost-effectiveness of the proposed approach vs. the current strategy based on visual inspection with acetic acid (VIA). The investigators believe that the AmpFire® test will have the potential to detect at least 90% of women with cervical precancer (performance). Similarly, the investigators anticipate that combining AmpFire® with AVE triage in a same-day screening-and-treatment strategy will be feasible and acceptable to patients and providers. The successful completion of this project will provide crucial data on the effectiveness of a self-sample, same-day screening-and-treatment approach with the potential to increase early detection while reducing loss to follow-up, ultimately resulting in increased adoption of this technology.

Sponsor: Atila Biosystems Inc.

Who Can Participate

Inclusion Criteria

Presence of a cervix

Exclusion Criteria

Cervical cancer screening in the past 2 years
Prior diagnosis or treatment of cervical cancer
Inability to tolerate a speculum exam

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Sunnyvale?

Yes, this clinical trial (NCT07232355) has an active research site in Sunnyvale, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Human Papilloma Virus Treatment Options in Sunnyvale, CA

If you're searching for human papilloma virus treatment options in Sunnyvale, CA, this clinical trial (NCT07232355) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Sunnyvale research site is actively enrolling participants for this clinical trial. You'll receive care from experienced human papilloma virus specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Ready to Join in Sunnyvale?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Sunnyvale, CA